Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06208748 · ClinicalTrials.gov registry record · Phase 2
SARC044: A Phase II Trial of Bezuclastinib in Combination With Sunitinib in Patients With GIST
A Phase 2 study of Gastrointestinal Stromal Tumors and GIST, sponsored by Sarcoma Alliance for Research through Collaboration.
- Active
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
- 4
- Study locations
NCT06208748: Active Phase 2 study of Gastrointestinal Stromal Tumors and GIST, sponsored by Sarcoma Alliance for Research through Collaboration.
NCT06208748 is a Phase 2 study of Gastrointestinal Stromal Tumors and GIST that is active but no longer recruiting, run by Sarcoma Alliance for Research through Collaboration. The registered enrollment target is 40 participants, below the 91-participant average among 10 other Gastrointestinal Stromal Tumors trials with a reported enrollment target (56% lower). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06208748, a Phase 2 study of Gastrointestinal Stromal Tumors and GIST, is active but no longer recruiting, sponsored by Sarcoma Alliance for Research through Collaboration.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
- 4
- Study locations
Study Summary
This is an open label, single arm, phase 2 trial investigating bezuclastinib plus sunitinib in patients with GIST who have previously progressed on sunitinib.
Primary Outcome
mPFS will be summarized with a Kaplan-Meier curve
Conditions Studied
Interventions
- DRUG Bezuclastinib in combination with sunitinib
Study Locations (4)
Florida
- Sylvester Comprehensive Cancer Center, University of Miami - Miami
Massachusetts
- Dana Farber Cancer Institute - Boston
Oregon
- Oregon Health & Science University - Portland
Pennsylvania
- Fox Chase Cancer Center - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2024-08-01 |
| Est. Completion | 2027-06 |
| Phase | Phase 2 |
What the registry record for NCT06208748 still lists
NCT06208748 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 91-participant average among 10 other Gastrointestinal Stromal Tumors trials with a reported enrollment target (56% lower).
The record links to 2 conditions, with Gastrointestinal Stromal Tumors appearing as the primary indexed condition, and to 1 intervention - of which Bezuclastinib in combination with sunitinib is the first listed.
NCT06208748 reports a single indexed study location in Florida, Massachusetts, Oregon.
Frequently Asked Questions
What is clinical trial NCT06208748 about?
NCT06208748 is a clinical study titled "SARC044: A Phase II Trial of Bezuclastinib in Combination With Sunitinib in Patients With GIST". This is an open label, single arm, phase 2 trial investigating bezuclastinib plus sunitinib in patients with GIST who have previously progressed on sunitinib.
What is the current status of trial NCT06208748?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2024-08-01. Estimated completion is 2027-06.
What conditions does trial NCT06208748 study?
This clinical trial studies the following conditions: Gastrointestinal Stromal Tumors, GIST.
What interventions are being tested in trial NCT06208748?
The interventions under investigation include: Bezuclastinib in combination with sunitinib (DRUG).
Who is sponsoring clinical trial NCT06208748?
This trial is sponsored by Sarcoma Alliance for Research through Collaboration, which has 20 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06208748 being conducted?
This trial has 4 study locations across Florida, Massachusetts, Oregon, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gastrointestinal Stromal Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06208748's enrollment target sits among peer trials
40 6th of 10 higher than 5 of 10 other Gastrointestinal Stromal Tumors trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Gastrointestinal Stromal Tumors trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
ctDNA-Guided Sunitinib And Regorafenib Therapy for GIST
RECRUITING · Phase 2
-
Imatinib TDM in GIST
RECRUITING · Phase 2
-
Phase 2 Study to Evaluate the Efficacy of Regorafenib in Specific GIST Mutation Subsets (KIT Exon 17, 18, or 14 Mutation and SDHB Deficient GIST) in the Post-imatinib Second-line Setting.
ACTIVE NOT RECRUITING · Phase 2
-
Temozolomide (TMZ) in Advanced Succinate Dehydrogenase (SDH)-Mutant/Deficient Gastrointestinal Stromal Tumor (GIST)
ACTIVE NOT RECRUITING · Phase 2
-
A Phase 2 Study of XL820 in Adults With Advanced GIST Resistant to Imatinib and/or Sunitinib
COMPLETED · Phase 2
-
A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI